BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21494666)

  • 1. Recombinant complement receptor 2 radiolabeled with [99mTc(CO)3]+: a potential new radiopharmaceutical for imaging activated complement.
    Badar A; DeFreitas S; McDonnell JM; Yahya N; Thakor D; Razavi R; Smith R; Sacks S; Mullen GE
    PLoS One; 2011 Apr; 6(4):e18275. PubMed ID: 21494666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient site-specific radiolabeling of a modified C2A domain of synaptotagmin I with [99mTc(CO)3]+: a new radiopharmaceutical for imaging cell death.
    Tavaré R; Torres Martin De Rosales R; Blower PJ; Mullen GE
    Bioconjug Chem; 2009 Nov; 20(11):2071-81. PubMed ID: 19874007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Invasive whole-body detection of complement activation using radionuclide imaging in a mouse model of myocardial ischaemia-reperfusion injury.
    Sharif-Paghaleh E; Yap ML; Puhl SL; Badar A; Torres JB; Chuamsaamarkkee K; Kampmeier F; Smith RA; Clark J; Blower PJ; Sacks S; Mullen GE
    Sci Rep; 2017 Nov; 7(1):16090. PubMed ID: 29170426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive Imaging of Activated Complement in Ischemia-Reperfusion Injury Post-Cardiac Transplant.
    Sharif-Paghaleh E; Yap ML; Meader LL; Chuamsaamarkkee K; Kampmeier F; Badar A; Smith RA; Sacks S; Mullen GE
    Am J Transplant; 2015 Sep; 15(9):2483-90. PubMed ID: 25906673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection.
    Carel JC; Myones BL; Frazier B; Holers VM
    J Biol Chem; 1990 Jul; 265(21):12293-9. PubMed ID: 1695627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational analysis of the complement receptor type 2 (CR2/CD21)-C3d interaction reveals a putative charged SCR1 binding site for C3d.
    Hannan JP; Young KA; Guthridge JM; Asokan R; Szakonyi G; Chen XS; Holers VM
    J Mol Biol; 2005 Feb; 346(3):845-58. PubMed ID: 15713467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydrodynamic, electron microscopic, and ligand-binding analysis of the Epstein-Barr virus/C3dg receptor (CR2).
    Moore MD; DiScipio RG; Cooper NR; Nemerow GR
    J Biol Chem; 1989 Dec; 264(34):20576-82. PubMed ID: 2555366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg.
    Guthridge JM; Rakstang JK; Young KA; Hinshelwood J; Aslam M; Robertson A; Gipson MG; Sarrias MR; Moore WT; Meagher M; Karp D; Lambris JD; Perkins SJ; Holers VM
    Biochemistry; 2001 May; 40(20):5931-41. PubMed ID: 11352728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface.
    Guthridge JM; Young K; Gipson MG; Sarrias MR; Szakonyi G; Chen XS; Malaspina A; Donoghue E; James JA; Lambris JD; Moir SA; Perkins SJ; Holers VM
    J Immunol; 2001 Nov; 167(10):5758-66. PubMed ID: 11698449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis.
    Kovacs JM; Hannan JP; Eisenmesser EZ; Holers VM
    J Biol Chem; 2009 Apr; 284(14):9513-20. PubMed ID: 19164292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delineation of the complement receptor type 2-C3d complex by site-directed mutagenesis and molecular docking.
    Shaw CD; Storek MJ; Young KA; Kovacs JM; Thurman JM; Holers VM; Hannan JP
    J Mol Biol; 2010 Dec; 404(4):697-710. PubMed ID: 20951140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220.
    Sarrias MR; Franchini S; Canziani G; Argyropoulos E; Moore WT; Sahu A; Lambris JD
    J Immunol; 2001 Aug; 167(3):1490-9. PubMed ID: 11466369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational analyses reveal that the staphylococcal immune evasion molecule Sbi and complement receptor 2 (CR2) share overlapping contact residues on C3d: implications for the controversy regarding the CR2/C3d cocrystal structure.
    Isenman DE; Leung E; Mackay JD; Bagby S; van den Elsen JM
    J Immunol; 2010 Feb; 184(4):1946-55. PubMed ID: 20083651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein Barr virus/complement C3d receptor is an interferon alpha receptor.
    Delcayre AX; Salas F; Mathur S; Kovats K; Lotz M; Lernhardt W
    EMBO J; 1991 Apr; 10(4):919-26. PubMed ID: 1849076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).
    Clemenza L; Isenman DE
    J Immunol; 2000 Oct; 165(7):3839-48. PubMed ID: 11034390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure of complement receptor (CR) 2 and CR2-C3d complexes.
    Hannan J; Young K; Szakonyi G; Overduin MJ; Perkins SJ; Chen X; Holers VM
    Biochem Soc Trans; 2002 Nov; 30(Pt 6):983-9. PubMed ID: 12440958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C3d adjuvant activity is reduced by altering residues involved in the electronegative binding of C3d to CR2.
    Toapanta FR; DeAlmeida DR; Dunn MD; Ross TM
    Immunol Lett; 2010 Mar; 129(1):32-8. PubMed ID: 20064559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutting edge: members of the Staphylococcus aureus extracellular fibrinogen-binding protein family inhibit the interaction of C3d with complement receptor 2.
    Ricklin D; Ricklin-Lichtsteiner SK; Markiewski MM; Geisbrecht BV; Lambris JD
    J Immunol; 2008 Dec; 181(11):7463-7. PubMed ID: 19017934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of complement receptor type 2 and endogenous complement in the humoral immune response to conjugates of complement C3d and pneumococcal serotype 14 capsular polysaccharide.
    Mitsuyoshi JK; Hu Y; Test ST
    Infect Immun; 2005 Nov; 73(11):7311-6. PubMed ID: 16239528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biophysical investigations of complement receptor 2 (CD21 and CR2)-ligand interactions reveal amino acid contacts unique to each receptor-ligand pair.
    Kovacs JM; Hannan JP; Eisenmesser EZ; Holers VM
    J Biol Chem; 2010 Aug; 285(35):27251-27258. PubMed ID: 20558730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.